{"id":449987,"date":"2021-03-03T16:08:15","date_gmt":"2021-03-03T21:08:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=449987"},"modified":"2021-03-03T16:08:15","modified_gmt":"2021-03-03T21:08:15","slug":"avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/","title":{"rendered":"Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TUSTIN, Calif., March  03, 2021  (GLOBE NEWSWIRE) &#8212; Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company&#8217;s 10.50% Series E Convertible Preferred Stock (the &#8220;Series E Preferred Stock&#8221;).<\/p>\n<p align=\"justify\">The quarterly dividend on the Series E Preferred Stock is payable on April 1, 2021 to holders of record at the close of business on March 15, 2021.<\/p>\n<p align=\"justify\">The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from January 1, 2021 through March 31, 2021. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol &#8220;CDMOP&#8221;.<\/p>\n<p align=\"justify\">\n        <strong>About<\/strong><br \/>\n        <strong>\u00a0<\/strong><br \/>\n        <strong>Avid Bioservices, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Avid Bioservices\u00a0is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid&#8217;s services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W9cJrvYk2JNC86AKYn5ZK2yCU-WA1FM_ysj00RFOiWV5gmj80x2AczrQTlt0wqShGTORcK1b2lmN0RaiRv8-8g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.avidbio.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzg0OCM0MDQ2ODU2IzIwMDk0NDI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e0399091-5d84-4d28-a4c6-05b7c4a3d3ee\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contacts:\r\nStephanie Diaz (Investors)\r\nVida Strategic Partners\r\n415-675-7401\r\nsdiaz@vidasp.com\r\n\r\nTim Brons (Media)\r\nVida Strategic Partners\r\n415-675-7402\r\ntbrons@vidasp.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TUSTIN, Calif., March 03, 2021 (GLOBE NEWSWIRE) &#8212; Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company&#8217;s 10.50% Series E Convertible Preferred Stock (the &#8220;Series E Preferred Stock&#8221;). The quarterly dividend on the Series E Preferred Stock is payable on April 1, 2021 to holders of record at the close of business on March 15, 2021. The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-449987","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TUSTIN, Calif., March 03, 2021 (GLOBE NEWSWIRE) &#8212; Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company&#8217;s 10.50% Series E Convertible Preferred Stock (the &#8220;Series E Preferred Stock&#8221;). The quarterly dividend on the Series E Preferred Stock is payable on April 1, 2021 to holders of record at the close of business on March 15, 2021. The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, &hellip; Continue reading &quot;Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-03T21:08:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzg0OCM0MDQ2ODU2IzIwMDk0NDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock\",\"datePublished\":\"2021-03-03T21:08:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\\\/\"},\"wordCount\":285,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mzg0OCM0MDQ2ODU2IzIwMDk0NDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\\\/\",\"name\":\"Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mzg0OCM0MDQ2ODU2IzIwMDk0NDI=\",\"datePublished\":\"2021-03-03T21:08:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mzg0OCM0MDQ2ODU2IzIwMDk0NDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mzg0OCM0MDQ2ODU2IzIwMDk0NDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/","og_locale":"en_US","og_type":"article","og_title":"Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock - Market Newsdesk","og_description":"TUSTIN, Calif., March 03, 2021 (GLOBE NEWSWIRE) &#8212; Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company&#8217;s 10.50% Series E Convertible Preferred Stock (the &#8220;Series E Preferred Stock&#8221;). The quarterly dividend on the Series E Preferred Stock is payable on April 1, 2021 to holders of record at the close of business on March 15, 2021. The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, &hellip; Continue reading \"Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-03T21:08:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzg0OCM0MDQ2ODU2IzIwMDk0NDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock","datePublished":"2021-03-03T21:08:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/"},"wordCount":285,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzg0OCM0MDQ2ODU2IzIwMDk0NDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/","name":"Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzg0OCM0MDQ2ODU2IzIwMDk0NDI=","datePublished":"2021-03-03T21:08:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzg0OCM0MDQ2ODU2IzIwMDk0NDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mzg0OCM0MDQ2ODU2IzIwMDk0NDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avid-bioservices-declares-quarterly-dividend-on-its-series-e-convertible-preferred-stock-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=449987"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449987\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=449987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=449987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=449987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}